CL2017001760A1 - Compuestos co-agonistas de gip y glp-1 - Google Patents
Compuestos co-agonistas de gip y glp-1Info
- Publication number
- CL2017001760A1 CL2017001760A1 CL2017001760A CL2017001760A CL2017001760A1 CL 2017001760 A1 CL2017001760 A1 CL 2017001760A1 CL 2017001760 A CL2017001760 A CL 2017001760A CL 2017001760 A CL2017001760 A CL 2017001760A CL 2017001760 A1 CL2017001760 A1 CL 2017001760A1
- Authority
- CL
- Chile
- Prior art keywords
- gip
- glucose
- glp
- agonist compounds
- peptide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 4
- 239000008103 glucose Substances 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract 1
- 101710176384 Peptide 1 Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 abstract 1
- 239000000859 incretin Substances 0.000 abstract 1
- 230000002473 insulinotropic effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Child & Adolescent Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS MIMÉTICOS DEL PÉPTIDO DE INCRETINA DUAL QUE AGONIZA LOS RECEPTORES PARA TANTO EL POLIPÉPTIDO INSULINOTRÓPICO DEPENDIENTE DE LA GLUCOSA HUMANA (GIP) Y PÉPTIDO-1 SIMILAR AL GLUCAGÓN (GLP-1), Y PUEDEN SER ÚTILES PARA TRATAR DIABETES MELLITUS TIPO 2 (T2D).</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101488P | 2015-01-09 | 2015-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001760A1 true CL2017001760A1 (es) | 2018-03-16 |
Family
ID=55315708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001760A CL2017001760A1 (es) | 2015-01-09 | 2017-07-03 | Compuestos co-agonistas de gip y glp-1 |
Country Status (46)
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106456589B (zh) | 2013-12-18 | 2020-07-07 | 斯克利普斯研究所 | 修饰的治疗剂、订合的肽脂质缀合物及其组合物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| EP3624828B1 (en) * | 2017-05-18 | 2024-08-07 | Merck Sharp & Dohme LLC | Pharmaceutical formulation comprising incretin-insulin conjugates |
| MA46990B1 (fr) | 2017-08-24 | 2024-03-29 | Novo Nordisk As | Compositions glp-1 et ses utilisations |
| TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2019140030A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| MX2020007598A (es) | 2018-02-02 | 2020-09-03 | Novo Nordisk As | Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante. |
| CN112135832A (zh) | 2018-03-22 | 2020-12-25 | 维京治疗公司 | 化合物的晶型和制备化合物的晶型的方法 |
| TWI707865B (zh) * | 2018-05-04 | 2020-10-21 | 丹麥商諾佛 儂迪克股份有限公司 | Gip衍生物及其用途 |
| TWI705820B (zh) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| MY197569A (en) * | 2018-07-23 | 2023-06-25 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| WO2020023382A1 (en) * | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Methods of using a gip/glp1 co-agonist for therapy |
| EP4450127A3 (en) * | 2018-07-23 | 2025-01-01 | Eli Lilly and Company | Method of using a gip/glp1 co-agonist for diabetes |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| JP6564539B1 (ja) | 2018-09-14 | 2019-08-21 | 長瀬産業株式会社 | スルホン酸化合物によるペプチド精製方法 |
| EP3856339A1 (en) | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| JP2022510691A (ja) | 2018-12-05 | 2022-01-27 | バイキング・セラピューティクス・インコーポレイテッド | 線維症及び炎症の処置のための組成物 |
| TWI799680B (zh) * | 2019-01-29 | 2023-04-21 | 美商美國禮來大藥廠 | 製備gip/glp1雙重促效劑之方法 |
| GB201908424D0 (en) | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| PE20221049A1 (es) | 2019-08-19 | 2022-06-30 | Lilly Co Eli | Metodos para preparar analogos de incretina |
| WO2021066600A1 (ko) | 2019-10-04 | 2021-04-08 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
| CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| AR120714A1 (es) * | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| AR121093A1 (es) | 2020-01-23 | 2022-04-20 | Lilly Co Eli | Compuestos coagonistas de gip / glp1 |
| TW202140058A (zh) * | 2020-01-30 | 2021-11-01 | 美商美國禮來大藥廠 | 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途 |
| CN111253475B (zh) * | 2020-02-18 | 2021-03-09 | 江苏诺泰澳赛诺生物制药股份有限公司 | Glp-1激动多肽化合物及其盐与合成方法及用途 |
| AU2021229621B2 (en) | 2020-03-06 | 2023-08-31 | Sanofi | Peptides as selective GIP receptor agonists |
| CN113493503B (zh) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种肠促胰岛素类似物及其制备方法和用途 |
| TW202216746A (zh) * | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| CN116113429A (zh) * | 2020-07-06 | 2023-05-12 | 鸿绪生物医药科技（北京）有限公司 | 新型多肽及其治疗用途 |
| CA3184723A1 (en) | 2020-07-22 | 2022-01-27 | Patrick J. KNERR | Glp-1 and gip receptor co-agonists |
| TWI801942B (zh) | 2020-07-22 | 2023-05-11 | 丹麥商諾佛 儂迪克股份有限公司 | 適用於口服的glp-1及gip受體共促效劑 |
| WO2022068920A1 (en) * | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| WO2022080986A1 (ko) * | 2020-10-16 | 2022-04-21 | 한미약품 주식회사 | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
| US20240020543A1 (en) * | 2020-10-17 | 2024-01-18 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual agonists |
| EP4257597A4 (en) * | 2020-12-02 | 2025-04-02 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS |
| KR102691149B1 (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CN116867505A (zh) | 2021-02-17 | 2023-10-10 | 伊莱利利公司 | 替西帕肽治疗方法 |
| CA3208873A1 (en) * | 2021-02-17 | 2022-08-25 | Mathijs Christiaan Michael BUNCK | Gip/glp1 dual agonist therapeutic methods |
| US12215133B2 (en) | 2021-03-25 | 2025-02-04 | Brightgene Bio-Medical Technology Co., Ltd. | GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use |
| BR112023019389A2 (pt) | 2021-03-25 | 2023-11-28 | Brightgene Bio Medical Tech Co Ltd | Compostos, agonista de receptor duplo de gip e glp-1, composição farmacêutica compreendendo os mesmos, uso dos mesmos e método para prevenir e/ou tratar doenças associadas a distúrbios metabólicos |
| US20240226017A1 (en) | 2021-05-07 | 2024-07-11 | Eli Lilly And Company | Erodible tablet |
| GEAP202416419A (en) | 2021-05-13 | 2024-03-25 | Carmot Therapeutics Inc | Modulators of g-protein coupled receptors |
| CN118307645A (zh) * | 2021-05-28 | 2024-07-09 | 广东众生睿创生物科技有限公司 | 多肽的制备及其应用 |
| CA3222051A1 (en) * | 2021-06-01 | 2022-12-08 | Nanjing Zhihe Medicine Technology Co., Ltd. | Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof |
| MX2023014771A (es) | 2021-06-09 | 2024-03-19 | Scripps Research Inst | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. |
| TW202302624A (zh) * | 2021-06-18 | 2023-01-16 | 大陸商廣東眾生睿創生物科技有限公司 | 含內醯胺橋的多肽化合物 |
| CN118159552A (zh) | 2021-09-06 | 2024-06-07 | 赛诺菲 | 作为强效的且选择性的gip受体激动剂的新肽 |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023089594A1 (en) | 2021-11-22 | 2023-05-25 | Sun Pharmaceutical Industries Limited | Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| JP2025512980A (ja) * | 2022-04-07 | 2025-04-22 | 広東衆生睿創生物科技有限公司 | 糖尿病、肥満症およびその関連疾患を治療および／または予防するための医薬品の調製における、ポリペプチドの医薬的使用 |
| CN116947978A (zh) * | 2022-04-19 | 2023-10-27 | 北京惠之衡生物科技有限公司 | 一种glp-1和gip受体共激动多肽衍生物及其盐和制剂 |
| PE20250835A1 (es) | 2022-06-30 | 2025-03-21 | Lilly Co Eli | Composiciones y uso de la tirzepatida |
| EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| KR20250037523A (ko) * | 2022-07-13 | 2025-03-17 | 항저우 종메이화동 파마슈티칼 컴퍼니 리미티드 | Glp-1/gip 이중 효능제, 이의 제조 방법 및 이의 용도 |
| AU2023311214A1 (en) * | 2022-07-20 | 2025-02-27 | Viking Therapeutics, Inc. | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
| JP2025530743A (ja) | 2022-08-29 | 2025-09-17 | イーライ リリー アンド カンパニー | 経口投与のための組成物 |
| EP4587462A1 (en) * | 2022-09-15 | 2025-07-23 | Eli Lilly and Company | Gip and glp-1 dual agonist compounds |
| TW202412835A (zh) * | 2022-09-23 | 2024-04-01 | 大陸商博瑞生物醫藥(蘇州)股份有限公司 | 一種glp-1和gip雙受體激動劑藥物組合物及其用途 |
| KR20250096895A (ko) | 2022-10-05 | 2025-06-27 | 일라이 릴리 앤드 캄파니 | 인크레틴 합성을 위한 펩티드 |
| WO2024086601A2 (en) * | 2022-10-19 | 2024-04-25 | Eli Lilly And Company | Preserved gip/glp agonist compositions |
| CN117756913B (zh) * | 2022-11-07 | 2025-05-09 | 内蒙古博睿精创科技有限公司 | 一种新型长效多肽化合物、组合物及其应用 |
| AU2023385357A1 (en) | 2022-11-21 | 2025-06-05 | Eli Lilly And Company | Process for preparing a gip/glp1 dual agonist |
| JP2025539630A (ja) | 2022-12-16 | 2025-12-05 | ペプトロン インコーポレイテッド | Ｇｌｐ－１受容体アゴニストまたはその薬学的に許容可能な塩を含む徐放性微粒球およびその用途 |
| CN120435487A (zh) | 2022-12-29 | 2025-08-05 | 伊莱利利公司 | 制备替尔泊肽的工艺和中间体 |
| KR20250141711A (ko) | 2022-12-30 | 2025-09-29 | 알지파마 에이에스 | 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법 |
| IL322205A (en) | 2023-01-31 | 2025-09-01 | Lilly Co Eli | GIP/GLP1/GCG trireceptor agonists and their uses |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| AR132137A1 (es) * | 2023-03-15 | 2025-05-28 | Viking Therapeutics Inc | Composiciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| CN121001735A (zh) | 2023-03-31 | 2025-11-21 | 伊莱利利公司 | 用于治疗t2d的替尔泊肽 |
| CN121002051A (zh) * | 2023-04-11 | 2025-11-21 | 上海多米瑞生物技术有限公司 | 肠促胰素类似物及其制备方法和应用 |
| WO2024243243A1 (en) * | 2023-05-21 | 2024-11-28 | Carmot Therapeutics Inc. | Treatment of adults with overweight or obesity with or without weight-related comorbidities |
| CN116832141B (zh) * | 2023-06-06 | 2024-02-09 | 诺博泰科(成都)生物科技有限公司 | 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物 |
| AU2024284396A1 (en) | 2023-06-09 | 2026-01-08 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists |
| KR20240176455A (ko) | 2023-06-15 | 2024-12-24 | 노보 노르디스크 에이/에스 | 시클로덱스트린을 포함하는 약학적 제형 |
| AU2024306538A1 (en) | 2023-06-30 | 2025-12-04 | Zealand Pharma A/S | Combination therapy |
| CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
| WO2025069009A1 (en) | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
| CN117646017A (zh) * | 2023-11-02 | 2024-03-05 | 中国人民解放军海军军医大学 | Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用 |
| WO2025106773A1 (en) | 2023-11-17 | 2025-05-22 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent |
| WO2025114501A1 (en) | 2023-11-30 | 2025-06-05 | Novo Nordisk A/S | Tri-agonists of the glp-1, gip, and amylin receptors |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| CN120173084A (zh) * | 2023-12-20 | 2025-06-20 | 深圳翰宇药业股份有限公司 | 一种替尔泊肽的合成方法 |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025149039A1 (zh) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | 长效glp-1/gip双激动剂的药物组合物 |
| WO2025163674A1 (en) * | 2024-01-30 | 2025-08-07 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of tirzepatide |
| WO2025185605A1 (en) * | 2024-03-05 | 2025-09-12 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| WO2025191149A1 (en) | 2024-03-15 | 2025-09-18 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising dual gip and glp-1 receptor agonist |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
| US20250352622A1 (en) | 2024-05-15 | 2025-11-20 | Rose Pharma Inc. | Glp-1 formulations and their uses |
| CN118440155B (zh) * | 2024-07-11 | 2024-11-22 | 中国药科大学 | 一种双激动多肽化合物及其医药用途 |
| US12434008B1 (en) | 2025-02-26 | 2025-10-07 | Genzyme Corporation | Lock ring for a medicament delivery device |
| US12465697B1 (en) | 2025-02-26 | 2025-11-11 | Genzyme Corporation | Medicament delivery device |
| US12420017B1 (en) | 2025-02-26 | 2025-09-23 | Genzyme Corporation | Damping device for a medicament delivery device |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272652A1 (en) * | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| US20080171695A1 (en) | 2005-02-02 | 2008-07-17 | Novo Nordisk A/S | Insulin Derivatives |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN102170895A (zh) * | 2008-08-07 | 2011-08-31 | 益普生制药股份有限公司 | 葡萄糖依赖性促胰岛素多肽类似物 |
| JP5591243B2 (ja) | 2008-09-12 | 2014-09-17 | ノボ・ノルデイスク・エー／エス | ペプチド又はタンパク質のアシル化の方法 |
| CN101367873B (zh) * | 2008-10-08 | 2011-05-04 | 南开大学 | 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用 |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| GB0917072D0 (en) * | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| KR101091041B1 (ko) * | 2010-07-29 | 2011-12-09 | 고려대학교 산학협력단 | 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도 |
| CN103458920B (zh) | 2010-12-22 | 2016-07-06 | 印第安那大学科技研究公司 | 表现出gip受体活性的胰高血糖素类似物 |
| NZ611878A (en) * | 2010-12-22 | 2015-02-27 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| US9790262B2 (en) | 2011-04-05 | 2017-10-17 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| EP2718317B1 (en) | 2011-06-10 | 2018-11-14 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| WO2012171994A1 (en) | 2011-06-15 | 2012-12-20 | Novo Nordisk A/S | Multi substituted insulins |
| EP2758426B1 (en) | 2011-09-23 | 2019-08-07 | Novo Nordisk A/S | Novel glucagon analogues |
| BR112014015681A2 (pt) * | 2011-12-23 | 2019-09-24 | Boehringer Ingelheim Int | análogos de glucagon |
| EA028665B1 (ru) * | 2012-05-03 | 2017-12-29 | Зилэнд Фарма А/С | Соединения - двойные агонисты gip-glp-1 и способы |
| CN104583232B (zh) * | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| CN104955472A (zh) | 2012-10-17 | 2015-09-30 | 诺和诺德保健股份有限公司 | 用于生长激素递送的脂肪酸酰化的氨基酸 |
| SI2934568T1 (en) | 2012-12-21 | 2018-03-30 | Sanofi | Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon |
| UA118558C2 (uk) * | 2013-05-28 | 2019-02-11 | Такеда Фармасьютікал Компані Лімітед | Пептидна сполука |
-
2015
- 2015-01-09 JO JOP/2020/0119A patent/JOP20200119A1/ar unknown
- 2015-12-22 JO JOP/2015/0334A patent/JO3575B1/ar active
- 2015-12-22 TW TW104143220A patent/TWI582109B/zh active
- 2015-12-22 AR ARP150104252A patent/AR103242A1/es active IP Right Grant
-
2016
- 2016-01-05 EA EA201892057A patent/EA035055B1/ru unknown
- 2016-01-05 KR KR1020217037823A patent/KR20210145311A/ko not_active Ceased
- 2016-01-05 IL IL281545A patent/IL281545B2/en unknown
- 2016-01-05 SI SI201630358T patent/SI3242887T1/sl unknown
- 2016-01-05 PE PE2017001142A patent/PE20170954A1/es unknown
- 2016-01-05 ME MEP-2019-238A patent/ME03494B/me unknown
- 2016-01-05 MY MYPI2017702464A patent/MY193616A/en unknown
- 2016-01-05 DK DK16703620.1T patent/DK3242887T3/da active
- 2016-01-05 CR CR20170310A patent/CR20170310A/es unknown
- 2016-01-05 MA MA050422A patent/MA50422A/fr unknown
- 2016-01-05 KR KR1020177018584A patent/KR101957620B1/ko active Active
- 2016-01-05 LT LT16703620T patent/LT3242887T/lt unknown
- 2016-01-05 AU AU2016205435A patent/AU2016205435B2/en active Active
- 2016-01-05 CN CN201680005007.XA patent/CN107207576B/zh active Active
- 2016-01-05 KR KR1020247028815A patent/KR20240135032A/ko active Pending
- 2016-01-05 CN CN202011598548.2A patent/CN112608377B/zh active Active
- 2016-01-05 EP EP19188718.1A patent/EP3597662A1/en active Pending
- 2016-01-05 MA MA41315A patent/MA41315B1/fr unknown
- 2016-01-05 PT PT167036201T patent/PT3242887T/pt unknown
- 2016-01-05 CA CA2973352A patent/CA2973352C/en active Active
- 2016-01-05 MD MDE20170269 patent/MD3242887T2/ro unknown
- 2016-01-05 NZ NZ771547A patent/NZ771547A/en unknown
- 2016-01-05 TN TN2017000198A patent/TN2017000198A1/en unknown
- 2016-01-05 JP JP2016549352A patent/JP6219534B2/ja active Active
- 2016-01-05 SG SG11201705603YA patent/SG11201705603YA/en unknown
- 2016-01-05 EA EA201791281A patent/EA031591B1/ru unknown
- 2016-01-05 WO PCT/US2016/012124 patent/WO2016111971A1/en not_active Ceased
- 2016-01-05 RS RS20191110A patent/RS59146B1/sr unknown
- 2016-01-05 US US14/987,791 patent/US9474780B2/en active Active
- 2016-01-05 PL PL16703620T patent/PL3242887T3/pl unknown
- 2016-01-05 HU HUE16703620A patent/HUE045860T2/hu unknown
- 2016-01-05 NZ NZ771043A patent/NZ771043A/en unknown
- 2016-01-05 IL IL320236A patent/IL320236A/en unknown
- 2016-01-05 KR KR1020237004037A patent/KR20230023822A/ko not_active Ceased
- 2016-01-05 EA EA202090392A patent/EA202090392A3/ru unknown
- 2016-01-05 HR HRP20191614 patent/HRP20191614T1/hr unknown
- 2016-01-05 KR KR1020197006498A patent/KR102330764B1/ko active Active
- 2016-01-05 EP EP16703620.1A patent/EP3242887B1/en active Active
- 2016-01-05 NZ NZ732000A patent/NZ732000A/en unknown
- 2016-01-05 PH PH1/2017/501252A patent/PH12017501252B1/en unknown
- 2016-01-05 ES ES16703620T patent/ES2747928T3/es active Active
- 2016-01-05 MX MX2017008927A patent/MX382753B/es unknown
- 2016-05-01 UA UAA201707109A patent/UA118239C2/uk unknown
-
2017
- 2017-05-24 IL IL252499A patent/IL252499B/en active IP Right Grant
- 2017-06-01 SV SV2017005453A patent/SV2017005453A/es unknown
- 2017-06-08 ZA ZA2017/03930A patent/ZA201703930B/en unknown
- 2017-06-22 DO DO2017000153A patent/DOP2017000153A/es unknown
- 2017-07-03 CL CL2017001760A patent/CL2017001760A1/es unknown
- 2017-07-05 CO CONC2017/0006737A patent/CO2017006737A2/es unknown
- 2017-07-05 MX MX2021005835A patent/MX2021005835A/es unknown
- 2017-07-07 EC ECIEPI201743648A patent/ECSP17043648A/es unknown
- 2017-09-27 JP JP2017186721A patent/JP6545766B2/ja active Active
-
2019
- 2019-06-19 JP JP2019113638A patent/JP6754867B2/ja active Active
- 2019-09-12 CY CY20191100957T patent/CY1122028T1/el unknown
-
2020
- 2020-08-04 IL IL276492A patent/IL276492B/en active IP Right Grant
-
2023
- 2023-01-31 FR FR23C1006C patent/FR23C1006I2/fr active Active
- 2023-01-31 LT LTPA2023504C patent/LTC3242887I2/lt unknown
- 2023-01-31 HU HUS2300006C patent/HUS2300006I1/hu unknown
- 2023-01-31 CY CY2023003C patent/CY2023003I2/el unknown
- 2023-02-02 NO NO2023005C patent/NO2023005I1/no unknown
- 2023-02-02 FI FIC20230005C patent/FIC20230005I1/fi unknown
- 2023-02-03 LU LU00296C patent/LUC00296I2/fr unknown
- 2023-02-07 NL NL301217C patent/NL301217I2/nl unknown
-
2024
- 2024-02-15 AR ARP240100340A patent/AR131857A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001760A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| CL2019001465A1 (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip. | |
| CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| MX2019006260A (es) | Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad. | |
| UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| CL2017003185A1 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| AR099977A1 (es) | Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4 | |
| SA518391903B1 (ar) | معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي | |
| DOP2017000102A (es) | Coagonistas de los receptores de glucagón y de glp-1 | |
| EA201690660A1 (ru) | Соединения и способы на основе двойного агониста гип и гпп-1 | |
| MX382502B (es) | Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1). | |
| MX394179B (es) | Liraglutida en afecciones cardiovasculares. | |
| MX2015009433A (es) | Polipeptidos novedosos que tienen actividad liberadora de hormonas de la saciedad. | |
| AR107282A1 (es) | Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip) |